Despite a crowded GLP-1 drug development field, Structure's oral small molecule approach and strong financial position offer ...

Type 2 diabetes (T2D) and obesity increase the risk of hematologic cancers. The impact of Glucagon-like peptide–1 receptor ...

Chilean foodtech firm NotCo says it expects to be profitable in Chile, Argentina, Colombia, and Peru in Q2, 2025.

Glucagon-like peptide 1 receptor agonists appear to reduce the risk of age-related macular degeneration and primary open-angle glaucoma.

GLP-1 RA use is associated with better graft and patient survival among kidney transplant recipients with diabetes.

The drug will be priced at ₹3,500 for a 2.5 mg vial and ₹4,375 for the 5 mg vial. The injectable, to be taken once a week, ...

The demand for glucagon-like peptide 1 (GLP-1s) receptor agonists for overweight/obesity has created a clinical conundrum for ...

Eli Lilly launched its weight loss drug Mounjaro in India. According to the company, the injection is supposed to be taken ...

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder with a rapidly increasing global prevalence. It is primarily ...

Eli Lilly launches Mounjaro, the much-awaited diabetes drug, in India. It is priced at ₹3,500 for 2.5 mg. Mounjaro and ...

The popular anti-obesity drug Mounjaro has finally been launched in India. The development comes after Eli Lilly received ...

Lilly launches Mounjaro in India, offering new option to treat obesity and type 2 diabetes: Our Bureau, Bengaluru Thursday, ...